TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00550446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
Study: NCT03943836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients in the music group will listen to classical music during their dental procedure.
Study: NCT03807609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX -30. Condition with an acute exercise set 30 minutes before lunch
Description: The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX-180. condition with an acute exercise set 180 minutes before lunch
Description: The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study: NCT04052945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA acupuncture
Description: For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 ).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6).
Study: NCT02182232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00301561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified follow-up approach of ARV treatment
Description: Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up approach of ARV treatment
Description: Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed
Study: NCT00458146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-093
Description: 60mg MM-093/week as a subcutaneous injection for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MM-093
Description: 60mg MM-093/week as a subcutaneous injection for 3 months
Study: NCT04374383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phthalocyanine Dye
Description: following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LASER assisted SRP
Description: LASER assisted SRP will be carried

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASER assisted SRP
Description: LASER assisted SRP will be carried
Study: NCT01859611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriActive+ RF
Description: Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
Study: NCT04614571

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gluten Powder
Description: Administered orally daily for 14 days
Study: NCT00687947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGRP
Description: CGRP (0.5 ug/min) infused intravenously over 20 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGRP
Description: CGRP (0.5 ug/min) infused intravenously over 20 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP
Description: CGRP (0.5 ug/min) infused intravenously over 20 min
Study: NCT03371745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trophectoderm biopsy
Description: Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreservation
Description: Rapid freezing using vitrification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreservation
Description: Rapid freezing using vitrification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: Transfer of embryo that has been cultured in vitro into the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: Transfer of embryo that has been cultured in vitro into the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: Transfer of embryo that has been cultured in vitro into the uterus
Study: NCT01896453

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
Study: NCT06538467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension exercise with inertial load
Description: Hip extension exercise with inertial load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension exercise with gravitational load
Description: Hip extension exercise with gravitational load
Study: NCT02780505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples.
Study: NCT03996226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 oral tablets.
Study: NCT02206737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nicotine e-cigarette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose nicotine e-cigarette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose nicotine e-cigarette
Study: NCT04102488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Six-step hand hygiene technique with an application time of 30 seconds
Description: Six-step hand hygiene technique with an application time of 30 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Six-step hand hygiene technique with an application time of 15 seconds
Description: Six-step hand hygiene technique with an application time of 15 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-step hand hygiene technique with an application time of 30 seconds
Description: Three-step hand hygiene technique with an application time of 30 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-step hand hygiene technique with an application time of 15 seconds
Description: Three-step hand hygiene technique with an application time of 15 seconds
Study: NCT02780505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement.
Study: NCT00590525

Intervention type: PROCEDURE
Intervention: Cardioversion
Description: Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
Study: NCT03427983

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hydrodissection
Description: Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regular Injection
Description: Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
Study: NCT01756144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Study: NCT02602483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03708705

Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation

Intervention type: OTHER
Intervention: Risk model of tumor relapse
Description: High risk factor model of tumor relapse after liver transplantation
Study: NCT00992719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated H1N1 Vaccine
Description: H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
Study: NCT04662437

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing
Description: From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood was collected for biochemistry testing
Description: From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
Study: NCT03385577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer
Description: 'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
Study: NCT01183442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: orally administered 2800 IU of vitamin D or placebo daily
Study: NCT01153789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthoptic rehabilitation
Description: Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.

Intervention type: OTHER
Group type: OTHER
Intervention: Orthoptic diagnostic
Description: postural, oculomotor and orthoptics tests
Study: NCT01183442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: orally administered 2800 IU of vitamin D or placebo daily
Study: NCT02505893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human pancreatic islet
Description: One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
Study: NCT01383239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Postoperative Therapy
Description: All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Physical Therapy
Description: All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
Study: NCT04157218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)
Description: The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)
Description: The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threads used in this study are absorbable Aptos
Description: The threads will be inserted to the cheeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threads used in this study are absorbable Aptos
Description: The threads will be inserted to the cheeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threads used in this study are absorbable Aptos
Description: The threads will be inserted to the cheeks
Study: NCT04197479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet
Study: NCT02609802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
Study: NCT00884416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib dose escalation
Description: Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid